Last reviewed · How we verify

NKTR-214 — Competitive Intelligence Brief

NKTR-214 (NKTR-214) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Engineered cytokine; IL-2 receptor agonist. Area: Oncology.

phase 3 Engineered cytokine; IL-2 receptor agonist IL-2 receptor (IL-2R); preferentially IL-2Rβγ over IL-2Rα Oncology Biologic Live · refreshed every 30 min

Target snapshot

NKTR-214 (NKTR-214) — Bristol-Myers Squibb. NKTR-214 is an engineered interleukin-2 (IL-2) cytokine that preferentially activates and expands CD8+ T cells and NK cells to enhance anti-tumor immune responses.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
NKTR-214 TARGET NKTR-214 Bristol-Myers Squibb phase 3 Engineered cytokine; IL-2 receptor agonist IL-2 receptor (IL-2R); preferentially IL-2Rβγ over IL-2Rα
NL003 NL003 Beijing Northland Biotech. Co., Ltd. phase 3 Cytokine / IL-2 receptor agonist IL-2 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Engineered cytokine; IL-2 receptor agonist class)

  1. Bristol-Myers Squibb · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NKTR-214 — Competitive Intelligence Brief. https://druglandscape.com/ci/nktr-214. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: